Mary Keebler
Advanced Heart Failure and Transplant Cardiology · Pittsburgh, PANPI 1144201096
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $538 of the $707 with a category attached, or 76.1%. One Lambda, Inc. accounts for 76.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $538 and has fallen 95.1% since, to $26 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in PA, where the typical reported total is $4,440.
Across 5 payments — averaging $141.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- One Lambda, Inc.$538
- Abbott$72
- Medtronic$71
- Abiomed$26
Across 39 payments — averaging $2226.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$85K
- Medtronic$2K
What the payments were for
- Travel & lodging$53876%
- Food & beverage$16924%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$707 in reported general payments places this provider in the 15th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.
See all advanced heart failure and transplant cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 114 | $143,349 |
| JardianceEmpagliflozin | 106 | $124,304 |
| EliquisApixaban | 79 | $92,284 |
| Repatha SureclickEvolocumab | 68 | $50,510 |
| Sirolimus | 68 | $44,418 |
| Envarsus XrTacrolimus | 31 | $28,294 |
| Tacrolimus | 214 | $27,693 |
| FarxigaDapagliflozin Propanediol | 14 | $22,460 |
| Mycophenolic AcidMycophenolate Sodium | 26 | $14,595 |
| Mycophenolate Mofetil | 78 | $11,265 |
| Repatha SyringeEvolocumab | 20 | $7,277 |
| Bumetanide | 67 | $4,958 |
| Cyclosporine ModifiedCyclosporine, Modified | 20 | $3,093 |
| Clonidine | 20 | $2,802 |
| Potassium Chloride | 92 | $2,480 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Pittsburgh
- Andrew PogozelskiPittsburgh$401K
- Srinivas MuraliPittsburgh$39K
- Sideris FacarosPittsburgh$21K
- Matthew LanderPittsburgh$16K
- Gavin HickeyPittsburgh$5K
- Amresh RainaPittsburgh$4K
- Jenna SkowronskiPittsburgh$4K
- Ravi RamaniPittsburgh$4K
- Miguel Pinilla VeraPittsburgh$4K
- Anjali VaidyaPhiladelphia$762K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.